Advanced HCC: 2nd line treatment selection and the right time to switch

COR2ED Medical Education

Вміст надано COR2ED. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією COR2ED або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.

9M ago 29:25

MP3•Головна епізоду

COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2^nd line therapy.

In this podcast, the experts give an overview of the current 1^st and 2^nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2^nd line systemic therapies between Europe and USA.

The experts present their approach in making the decision to switch to 2^nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2^nd line therapy.

87 епізодів

#Science #COR2ED #Higher Education #Medical Education #Fitness #Podcasting Education #Medicine